You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGoserelin
Accession NumberDB00014  (BTD00113, BIOD00113)
TypeSmall Molecule
GroupsApproved
Description

Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.

Structure
Thumb
Synonyms
Goserelin
Goserelin acetate
ICI-118630
Zoladex
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Zoladeximplant3.6 mg/1subcutaneousAstra Zeneca Pharmaceuticals Lp2003-05-05Not applicableUs
Zoladeximplant10.8 mg/1subcutaneousAstra Zeneca Pharmaceuticals Lp2003-05-05Not applicableUs
Zoladex Inj Depot 3.6mgimplant3.6 mgsubcutaneousAstrazeneca Canada Inc1994-12-31Not applicableCanada
Zoladex LA Inj Depot 10.8mgimplant10.8 mgsubcutaneousAstrazeneca Canada Inc1996-08-28Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Goserelin acetate
Thumb
  • InChI Key: IKDXDQDKCZPQSZ-JHYYTBFNSA-N
  • Monoisotopic Mass: 1328.662568858
  • Average Mass: 1329.4624
DBSALT000093
Categories
UNII0F65R8P09N
CAS number65807-02-5
WeightAverage: 1269.4105
Monoisotopic: 1268.641439486
Chemical FormulaC59H84N18O14
InChI KeyInChIKey=BLCLNMBMMGCOAS-URPVMXJPSA-N
InChI
InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1
IUPAC Name
(2S)-1-[(2S)-2-[(2S)-2-[(2R)-3-(tert-butoxy)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-imidazol-5-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-4-methylpentanamido]-5-[(diaminomethylidene)amino]pentanoyl]-N-(carbamoylamino)pyrrolidine-2-carboxamide
SMILES
CC(C)C[[email protected]](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[[email protected]](CC1=CC=C(O)C=C1)NC(=O)[[email protected]](CO)NC(=O)[[email protected]](CC1=CNC2=CC=CC=C12)NC(=O)[[email protected]](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[[email protected]]1C(=O)NNC(N)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • Triptan
  • Alpha-amino acid amide
  • Phenylpropylamine
  • Amphetamine or derivatives
  • N-substituted-alpha-amino acid
  • Indole or derivatives
  • Indole
  • Pyrrolidine-2-carboxamide
  • Pyrrolidine carboxylic acid or derivatives
  • N-acylpyrrolidine
  • Phenol
  • Fatty acyl
  • Benzenoid
  • Hydrazinecarboxamide
  • Substituted pyrrole
  • 2-pyrrolidone
  • Pyrrolidone
  • N-acyl-amine
  • Fatty amide
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Semicarbazide
  • Pyrrolidine
  • Pyrrole
  • Imidazole
  • Azole
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Lactam
  • Guanidine
  • Carboxylic acid hydrazide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Ether
  • Dialkyl ether
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty.
PharmacodynamicsThe pharmacokinetics of goserelin have been determined in both male and female healthy volunteers and patients. In these studies, goserelin was administered as a single 250µg (aqueous solution) dose and as a single or multiple 3.6 mg depot dose by subcutaneous route.
Mechanism of actionGoserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels.
Related Articles
AbsorptionInactive orally, rapidly absorbed following subcutaneous administration.
Volume of distribution
  • 44.1 ± 13.6 L [subcutaneous administration of 250 mcg]
Protein binding27.3%
Metabolism

Hepatic

Route of eliminationClearance of goserelin following subcutaneous administration of a radiolabeled solution of goserelin was very rapid and occurred via a combination of hepatic and urinary excretion. More than 90% of a subcutaneous radiolabeled solution formulation dose of goserelin was excreted in urine.
Half life4-5 hours
Clearance
  • 121 +/- 42.4 mL/min [prostate cancer with 10.8 mg depot]
ToxicityNo experience of overdosage from clinical trials.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9771
Blood Brain Barrier-0.8816
Caco-2 permeable-0.7772
P-glycoprotein substrateSubstrate0.9016
P-glycoprotein inhibitor INon-inhibitor0.5834
P-glycoprotein inhibitor IINon-inhibitor0.8342
Renal organic cation transporterNon-inhibitor0.7673
CYP450 2C9 substrateNon-substrate0.7534
CYP450 2D6 substrateNon-substrate0.7806
CYP450 3A4 substrateSubstrate0.6353
CYP450 1A2 substrateNon-inhibitor0.8265
CYP450 2C9 inhibitorNon-inhibitor0.7506
CYP450 2D6 inhibitorNon-inhibitor0.8835
CYP450 2C19 inhibitorNon-inhibitor0.7254
CYP450 3A4 inhibitorNon-inhibitor0.6347
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9054
Ames testNon AMES toxic0.5851
CarcinogenicityNon-carcinogens0.6406
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6730 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8841
hERG inhibition (predictor II)Inhibitor0.5249
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Astrazeneca uk ltd
Packagers
Dosage forms
FormRouteStrength
Implantsubcutaneous10.8 mg/1
Implantsubcutaneous3.6 mg/1
Implantsubcutaneous3.6 mg
Implantsubcutaneous10.8 mg
Prices
Unit descriptionCostUnit
Zoladex 10.8 mg implant syringe1380.65USD syringe
Zoladex 3.6 mg implant syringe451.19USD syringe
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7118552 No2002-04-132022-04-13Us
US7220247 No2002-04-092022-04-09Us
US7500964 No2001-02-262021-02-26Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
logP-2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0283 mg/mLALOGPS
logP0.3ALOGPS
logP-5.2ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)9.27ChemAxon
pKa (Strongest Basic)10.82ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count18ChemAxon
Hydrogen Donor Count17ChemAxon
Polar Surface Area495.89 Å2ChemAxon
Rotatable Bond Count33ChemAxon
Refractivity325.84 m3·mol-1ChemAxon
Polarizability131.22 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Kripa S. Srivastava, Matthew R. Davis, “Solid Phase Peptide for the Production of Goserelin.” U.S. Patent US20100311946, issued December 09, 2010.

US20100311946
General ReferencesNot Available
External Links
ATC CodesL02AE03
AHFS Codes
  • 68:18.00
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (992 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Goserelin.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Goserelin.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Goserelin.
AmantadineAmantadine may increase the QTc-prolonging activities of Goserelin.
AmiodaroneGoserelin may increase the QTc-prolonging activities of Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Goserelin.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Goserelin.
AnagrelideGoserelin may increase the QTc-prolonging activities of Anagrelide.
ApomorphineApomorphine may increase the QTc-prolonging activities of Goserelin.
ArformoterolArformoterol may increase the QTc-prolonging activities of Goserelin.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Goserelin.
Arsenic trioxideGoserelin may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherGoserelin may increase the QTc-prolonging activities of Artemether.
AsenapineGoserelin may increase the QTc-prolonging activities of Asenapine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Goserelin.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Goserelin.
AzithromycinGoserelin may increase the QTc-prolonging activities of Azithromycin.
BedaquilineGoserelin may increase the QTc-prolonging activities of Bedaquiline.
BortezomibBortezomib may increase the QTc-prolonging activities of Goserelin.
BosutinibBosutinib may increase the QTc-prolonging activities of Goserelin.
BuserelinBuserelin may increase the QTc-prolonging activities of Goserelin.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.
CapromabGoserelin may decrease effectiveness of Capromab as a diagnostic agent.
CeritinibGoserelin may increase the QTc-prolonging activities of Ceritinib.
ChloroquineGoserelin may increase the QTc-prolonging activities of Chloroquine.
ChlorpromazineGoserelin may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Goserelin.
Choline C 11The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Goserelin.
CiprofloxacinGoserelin may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideGoserelin may increase the QTc-prolonging activities of Cisapride.
CitalopramGoserelin may increase the QTc-prolonging activities of Citalopram.
ClarithromycinGoserelin may increase the QTc-prolonging activities of Clarithromycin.
ClomipramineClomipramine may increase the QTc-prolonging activities of Goserelin.
ClozapineGoserelin may increase the QTc-prolonging activities of Clozapine.
Corifollitropin AlfaThe therapeutic efficacy of Corifollitropin Alfa can be increased when used in combination with Goserelin.
CrizotinibGoserelin may increase the QTc-prolonging activities of Crizotinib.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Goserelin.
DasatinibDasatinib may increase the QTc-prolonging activities of Goserelin.
DegarelixDegarelix may increase the QTc-prolonging activities of Goserelin.
DesfluraneDesflurane may increase the QTc-prolonging activities of Goserelin.
DesipramineDesipramine may increase the QTc-prolonging activities of Goserelin.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Goserelin.
DisopyramideGoserelin may increase the QTc-prolonging activities of Disopyramide.
DofetilideGoserelin may increase the QTc-prolonging activities of Dofetilide.
DolasetronGoserelin may increase the QTc-prolonging activities of Dolasetron.
DomperidoneGoserelin may increase the QTc-prolonging activities of Domperidone.
DoxepinDoxepin may increase the QTc-prolonging activities of Goserelin.
DronedaroneGoserelin may increase the QTc-prolonging activities of Dronedarone.
DroperidolGoserelin may increase the QTc-prolonging activities of Droperidol.
EliglustatGoserelin may increase the QTc-prolonging activities of Eliglustat.
EribulinEribulin may increase the QTc-prolonging activities of Goserelin.
ErythromycinGoserelin may increase the QTc-prolonging activities of Erythromycin.
EscitalopramGoserelin may increase the QTc-prolonging activities of Escitalopram.
EzogabineEzogabine may increase the QTc-prolonging activities of Goserelin.
FamotidineFamotidine may increase the QTc-prolonging activities of Goserelin.
FelbamateFelbamate may increase the QTc-prolonging activities of Goserelin.
FingolimodFingolimod may increase the QTc-prolonging activities of Goserelin.
FlecainideGoserelin may increase the QTc-prolonging activities of Flecainide.
FluconazoleFluconazole may increase the QTc-prolonging activities of Goserelin.
FluoxetineGoserelin may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolGoserelin may increase the QTc-prolonging activities of Flupentixol.
Fluticasone PropionateFluticasone Propionate may increase the QTc-prolonging activities of Goserelin.
FormoterolFormoterol may increase the QTc-prolonging activities of Goserelin.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Goserelin.
FosphenytoinFosphenytoin may increase the QTc-prolonging activities of Goserelin.
Gadobenic acidGoserelin may increase the QTc-prolonging activities of Gadobenate Dimeglumine.
GalantamineGalantamine may increase the QTc-prolonging activities of Goserelin.
GemifloxacinGoserelin may increase the QTc-prolonging activities of Gemifloxacin.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Goserelin.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Goserelin.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Goserelin.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Goserelin.
GranisetronGoserelin may increase the QTc-prolonging activities of Granisetron.
HaloperidolGoserelin may increase the QTc-prolonging activities of Haloperidol.
HistrelinHistrelin may increase the QTc-prolonging activities of Goserelin.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Goserelin.
IbandronateIbandronate may increase the QTc-prolonging activities of Goserelin.
IbutilideGoserelin may increase the QTc-prolonging activities of Ibutilide.
IloperidoneGoserelin may increase the QTc-prolonging activities of Iloperidone.
ImipramineImipramine may increase the QTc-prolonging activities of Goserelin.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Goserelin.
IndapamideIndapamide may increase the QTc-prolonging activities of Goserelin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Goserelin.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Goserelin.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Goserelin.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Goserelin.
Insulin HumanThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Goserelin.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Goserelin.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Goserelin.
IsradipineIsradipine may increase the QTc-prolonging activities of Goserelin.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Goserelin.
IvabradineIvabradine may increase the QTc-prolonging activities of Goserelin.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Goserelin.
LapatinibLapatinib may increase the QTc-prolonging activities of Goserelin.
LenvatinibGoserelin may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideGoserelin may increase the QTc-prolonging activities of Leuprolide.
LevofloxacinGoserelin may increase the QTc-prolonging activities of Levofloxacin.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin.
LithiumLithium may increase the QTc-prolonging activities of Goserelin.
LopinavirGoserelin may increase the QTc-prolonging activities of Lopinavir.
LumefantrineGoserelin may increase the QTc-prolonging activities of Lumefantrine.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Goserelin.
MefloquineMefloquine may increase the QTc-prolonging activities of Goserelin.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin.
MethadoneGoserelin may increase the QTc-prolonging activities of Methadone.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Goserelin.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Goserelin.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Goserelin.
MifepristoneMifepristone may increase the QTc-prolonging activities of Goserelin.
MirabegronMirabegron may increase the QTc-prolonging activities of Goserelin.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Goserelin.
MoexiprilMoexipril may increase the QTc-prolonging activities of Goserelin.
MoxifloxacinGoserelin may increase the QTc-prolonging activities of Moxifloxacin.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Goserelin.
NicardipineNicardipine may increase the QTc-prolonging activities of Goserelin.
NilotinibGoserelin may increase the QTc-prolonging activities of Nilotinib.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Goserelin.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Goserelin.
OctreotideOctreotide may increase the QTc-prolonging activities of Goserelin.
OfloxacinGoserelin may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Goserelin.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Goserelin.
OndansetronGoserelin may increase the QTc-prolonging activities of Ondansetron.
OsimertinibGoserelin may increase the QTc-prolonging activities of Osimertinib.
OxytocinOxytocin may increase the QTc-prolonging activities of Goserelin.
PaliperidoneGoserelin may increase the QTc-prolonging activities of Paliperidone.
PanobinostatGoserelin may increase the QTc-prolonging activities of Panobinostat.
ParoxetineParoxetine may increase the QTc-prolonging activities of Goserelin.
PasireotidePasireotide may increase the QTc-prolonging activities of Goserelin.
PazopanibGoserelin may increase the QTc-prolonging activities of Pazopanib.
PentamidineGoserelin may increase the QTc-prolonging activities of Pentamidine.
PerflutrenGoserelin may increase the QTc-prolonging activities of Perflutren.
PimozideGoserelin may increase the QTc-prolonging activities of Pimozide.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Goserelin.
PrimaquineGoserelin may increase the QTc-prolonging activities of Primaquine.
ProcainamideGoserelin may increase the QTc-prolonging activities of Procainamide.
PromazineGoserelin may increase the QTc-prolonging activities of Promazine.
PromethazinePromethazine may increase the QTc-prolonging activities of Goserelin.
PropafenoneGoserelin may increase the QTc-prolonging activities of Propafenone.
PropofolPropofol may increase the QTc-prolonging activities of Goserelin.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Goserelin.
QuetiapineGoserelin may increase the QTc-prolonging activities of Quetiapine.
QuinidineGoserelin may increase the QTc-prolonging activities of Quinidine.
QuinineGoserelin may increase the QTc-prolonging activities of Quinine.
RanolazineRanolazine may increase the QTc-prolonging activities of Goserelin.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Goserelin.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Goserelin.
RisperidoneRisperidone may increase the QTc-prolonging activities of Goserelin.
RitonavirRitonavir may increase the QTc-prolonging activities of Goserelin.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Goserelin.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Goserelin.
SaquinavirGoserelin may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Goserelin.
SertralineSertraline may increase the QTc-prolonging activities of Goserelin.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Goserelin.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Goserelin.
SorafenibSorafenib may increase the QTc-prolonging activities of Goserelin.
SotalolGoserelin may increase the QTc-prolonging activities of Sotalol.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Goserelin.
SulfisoxazoleGoserelin may increase the QTc-prolonging activities of Sulfisoxazole.
SunitinibSunitinib may increase the QTc-prolonging activities of Goserelin.
TacrolimusTacrolimus may increase the QTc-prolonging activities of Goserelin.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Goserelin.
TelavancinGoserelin may increase the QTc-prolonging activities of Telavancin.
TelithromycinGoserelin may increase the QTc-prolonging activities of Telithromycin.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Goserelin.
TetrabenazineGoserelin may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazineGoserelin may increase the QTc-prolonging activities of Thioridazine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Goserelin.
TizanidineTizanidine may increase the QTc-prolonging activities of Goserelin.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Goserelin.
TolterodineTolterodine may increase the QTc-prolonging activities of Goserelin.
ToremifeneGoserelin may increase the QTc-prolonging activities of Toremifene.
TrazodoneTrazodone may increase the QTc-prolonging activities of Goserelin.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Goserelin.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Goserelin.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Goserelin.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Goserelin.
VandetanibGoserelin may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Goserelin.
VemurafenibGoserelin may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Goserelin.
VilanterolVilanterol may increase the QTc-prolonging activities of Goserelin.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Goserelin.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Goserelin.
VorinostatVorinostat may increase the QTc-prolonging activities of Goserelin.
ZiprasidoneGoserelin may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolGoserelin may increase the QTc-prolonging activities of Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Luteinizing hormone receptor activity
Specific Function:
Receptor for lutropin-choriogonadotropic hormone. The activity of this receptor is mediated by G proteins which activate adenylate cyclase.
Gene Name:
LHCGR
Uniprot ID:
P22888
Molecular Weight:
78642.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x. [PubMed:20053189 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Peptide binding
Specific Function:
Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.
Gene Name:
GNRHR
Uniprot ID:
P30968
Molecular Weight:
37730.355 Da
References
  1. Kirby RS, Fitzpatrick JM, Clarke N: Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4. doi: 10.1111/j.1464-410X.2009.08924.x. [PubMed:20053189 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on May 24, 2016 02:06